Back to Clinical Trials Overview

Your search for "Liver Disorders" returned 32 results:


Genomics of Primary Biliary Cirrhosis
Principal Investigator(s): Joseph Odin

Natural History Study of Acute Hepatic Porphyria (AHP) with Recurrent Attacks
Principal Investigator(s): Manisha Balwani

A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection
Principal Investigator(s): Ponni Perumalswami

Simeprevir (SMV)+Sofosbuvir (SOF) with or without Ribavirin (RBV) for Interferon-intolerant or ineligible (IFN-II) Patients with Chronic Hepatitis C (CHC)
Principal Investigator(s): Ritu Agarwal

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Principal Investigator(s): Meena Bansal

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Principal Investigator(s): Meena Bansal

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
Principal Investigator(s): Meena Bansal

A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH)
Principal Investigator(s): Charissa Chang

A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Principal Investigator(s): Douglas Dieterich

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Principal Investigator(s): Charissa Chang

A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Jawad Ahmad

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study toInvestigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection
Principal Investigator(s): Rita Agarwal

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

A randomized double-blind controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B
Principal Investigator(s): Odin, Joseph A

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV
Principal Investigator(s): David Ferris

A Phase 2b Dose-Ranging Randomized Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624 a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis
Principal Investigator(s): Charissa Chang

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
Principal Investigator(s): Meena Bansal

HCC BRIDGE study: Bridge to better outcomes in HCC
Principal Investigator(s): Schwartz, Myron MD

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection
Principal Investigator(s): Rita Agarwal

A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3
Principal Investigator(s): Ponni Perumalswami

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by Electroporation in Select Nucleos(t)ide Analogue-treated, Chronic Hepatitis B Patients
Principal Investigator(s): Douglas Dieterich

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Principal Investigator(s): Peter Gorevic

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Principal Investigator(s): Ponni Perumalswami

A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Principal Investigator(s): Linda Law

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
Principal Investigator(s): Douglas Dieterich

A Phase 2 Randomized Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment
Principal Investigator(s): Jennifer Leong